 Terry Fry
Concepts (461)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 37 | 2025 | 321 | 8.880 |
Why?
| | T-Lymphocytes | 56 | 2025 | 1993 | 6.130 |
Why?
| | Antigens, CD19 | 24 | 2025 | 121 | 4.130 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2023 | 79 | 3.970 |
Why?
| | Graft vs Host Disease | 20 | 2023 | 248 | 3.620 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2024 | 288 | 3.100 |
Why?
| | CD8-Positive T-Lymphocytes | 19 | 2025 | 913 | 3.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 26 | 2023 | 614 | 3.020 |
Why?
| | Receptors, Antigen, T-Cell | 18 | 2023 | 718 | 2.790 |
Why?
| | Immunotherapy | 16 | 2024 | 640 | 2.680 |
Why?
| | Interleukin-7 | 23 | 2012 | 61 | 2.440 |
Why?
| | Dendritic Cells | 11 | 2016 | 484 | 2.420 |
Why?
| | Cancer Vaccines | 9 | 2018 | 172 | 1.910 |
Why?
| | CD4-Positive T-Lymphocytes | 11 | 2023 | 1095 | 1.830 |
Why?
| | Leukemia, Myeloid, Acute | 6 | 2025 | 622 | 1.780 |
Why?
| | Hematologic Neoplasms | 8 | 2023 | 155 | 1.770 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 8 | 2022 | 13 | 1.710 |
Why?
| | Lymphoma, B-Cell | 8 | 2025 | 106 | 1.690 |
Why?
| | Bone Marrow Transplantation | 9 | 2023 | 287 | 1.280 |
Why?
| | Lymphocyte Transfusion | 4 | 2017 | 21 | 1.250 |
Why?
| | Adoptive Transfer | 10 | 2019 | 224 | 1.150 |
Why?
| | Graft vs Leukemia Effect | 4 | 2017 | 12 | 1.010 |
Why?
| | Cytokines | 12 | 2022 | 2084 | 0.940 |
Why?
| | Dipeptides | 3 | 2014 | 50 | 0.930 |
Why?
| | Neoplasms | 13 | 2023 | 2643 | 0.910 |
Why?
| | H-Y Antigen | 5 | 2013 | 7 | 0.910 |
Why?
| | Mice | 43 | 2025 | 17757 | 0.900 |
Why?
| | T-Box Domain Proteins | 1 | 2025 | 98 | 0.900 |
Why?
| | Animals | 59 | 2025 | 36847 | 0.870 |
Why?
| | Antigens, Neoplasm | 5 | 2019 | 319 | 0.860 |
Why?
| | Graft vs Tumor Effect | 3 | 2021 | 8 | 0.830 |
Why?
| | Tumor Escape | 3 | 2021 | 42 | 0.750 |
Why?
| | Sialic Acid Binding Ig-like Lectin 3 | 1 | 2021 | 9 | 0.740 |
Why?
| | Humans | 109 | 2025 | 136765 | 0.720 |
Why?
| | Cell Adhesion Molecules | 1 | 2022 | 181 | 0.710 |
Why?
| | Receptors, Cytokine | 2 | 2024 | 36 | 0.700 |
Why?
| | Immune System | 5 | 2010 | 177 | 0.700 |
Why?
| | Perforin | 1 | 2020 | 19 | 0.690 |
Why?
| | Precursor Cells, B-Lymphoid | 2 | 2018 | 40 | 0.690 |
Why?
| | Cell Line, Tumor | 14 | 2025 | 3405 | 0.680 |
Why?
| | Leukemia | 5 | 2025 | 238 | 0.680 |
Why?
| | Thymus Gland | 6 | 2004 | 313 | 0.680 |
Why?
| | Retinal Neoplasms | 1 | 2020 | 25 | 0.680 |
Why?
| | Retinoblastoma | 1 | 2020 | 32 | 0.670 |
Why?
| | WT1 Proteins | 2 | 2018 | 15 | 0.670 |
Why?
| | Lymphoma | 2 | 2019 | 208 | 0.640 |
Why?
| | Recurrence | 13 | 2025 | 1055 | 0.640 |
Why?
| | Myelodysplastic Syndromes | 5 | 2023 | 134 | 0.640 |
Why?
| | Transplantation, Homologous | 9 | 2018 | 415 | 0.620 |
Why?
| | Adjuvants, Immunologic | 4 | 2014 | 226 | 0.620 |
Why?
| | T-Lymphocyte Subsets | 6 | 2023 | 425 | 0.620 |
Why?
| | Erythropoietin | 1 | 2020 | 95 | 0.610 |
Why?
| | Allergy and Immunology | 1 | 2019 | 43 | 0.600 |
Why?
| | Neoplasms, Experimental | 2 | 2019 | 176 | 0.600 |
Why?
| | Mice, Inbred C57BL | 17 | 2021 | 5749 | 0.560 |
Why?
| | Genetic Engineering | 2 | 2019 | 91 | 0.530 |
Why?
| | Boron Compounds | 2 | 2014 | 27 | 0.520 |
Why?
| | Calcitonin | 1 | 2016 | 27 | 0.520 |
Why?
| | Hematopoietic Stem Cells | 4 | 2016 | 402 | 0.520 |
Why?
| | Immunologic Memory | 8 | 2025 | 370 | 0.510 |
Why?
| | Cell Lineage | 2 | 2016 | 347 | 0.510 |
Why?
| | Child | 34 | 2023 | 21819 | 0.500 |
Why?
| | Cell Plasticity | 1 | 2016 | 35 | 0.490 |
Why?
| | Leukapheresis | 2 | 2017 | 21 | 0.490 |
Why?
| | Lymphocyte Activation | 11 | 2021 | 1150 | 0.480 |
Why?
| | Antigens, CD | 2 | 2017 | 521 | 0.480 |
Why?
| | Disease Models, Animal | 7 | 2020 | 4282 | 0.470 |
Why?
| | Donor Selection | 1 | 2015 | 77 | 0.460 |
Why?
| | Homeostasis | 6 | 2006 | 619 | 0.440 |
Why?
| | Apoptosis | 8 | 2019 | 2551 | 0.440 |
Why?
| | STAT1 Transcription Factor | 1 | 2014 | 73 | 0.440 |
Why?
| | Mice, Knockout | 7 | 2020 | 3008 | 0.440 |
Why?
| | Photopheresis | 2 | 2011 | 9 | 0.440 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 2 | 2014 | 46 | 0.430 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2015 | 220 | 0.420 |
Why?
| | Drug Resistance, Neoplasm | 5 | 2024 | 800 | 0.420 |
Why?
| | Rhabdomyosarcoma | 2 | 2014 | 72 | 0.420 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2025 | 868 | 0.410 |
Why?
| | Vaccination | 2 | 2012 | 1377 | 0.410 |
Why?
| | Recombinant Fusion Proteins | 4 | 2017 | 664 | 0.410 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2012 | 16 | 0.400 |
Why?
| | Boronic Acids | 1 | 2013 | 37 | 0.400 |
Why?
| | Lymphocyte Depletion | 8 | 2014 | 135 | 0.400 |
Why?
| | STAT3 Transcription Factor | 1 | 2014 | 206 | 0.390 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 434 | 0.380 |
Why?
| | Flow Cytometry | 6 | 2020 | 1180 | 0.380 |
Why?
| | Female | 48 | 2025 | 72795 | 0.370 |
Why?
| | Siblings | 4 | 2014 | 227 | 0.370 |
Why?
| | Antigens, CD34 | 2 | 2011 | 88 | 0.370 |
Why?
| | Neurotoxicity Syndromes | 2 | 2024 | 25 | 0.370 |
Why?
| | Mice, Inbred C3H | 4 | 2014 | 269 | 0.360 |
Why?
| | Adult | 30 | 2025 | 37631 | 0.360 |
Why?
| | Young Adult | 18 | 2025 | 13127 | 0.350 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 31 | 0.350 |
Why?
| | Living Donors | 3 | 2014 | 295 | 0.350 |
Why?
| | Neoplasm, Residual | 3 | 2020 | 133 | 0.350 |
Why?
| | Antigen Presentation | 2 | 2009 | 216 | 0.350 |
Why?
| | Neoplasm Metastasis | 3 | 2016 | 657 | 0.340 |
Why?
| | Receptors, Interleukin-7 | 5 | 2011 | 28 | 0.330 |
Why?
| | Adolescent | 23 | 2025 | 21382 | 0.330 |
Why?
| | Signal Transduction | 7 | 2024 | 5076 | 0.330 |
Why?
| | Male | 40 | 2025 | 67311 | 0.320 |
Why?
| | Transplantation Conditioning | 4 | 2018 | 170 | 0.320 |
Why?
| | Lymphocyte Count | 4 | 2017 | 150 | 0.320 |
Why?
| | Gene Expression | 5 | 2020 | 1500 | 0.310 |
Why?
| | Receptors, Interferon | 1 | 2009 | 52 | 0.300 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2009 | 251 | 0.300 |
Why?
| | Interleukin-10 | 1 | 2011 | 302 | 0.300 |
Why?
| | Sarcoma, Ewing | 2 | 2012 | 96 | 0.300 |
Why?
| | Models, Immunological | 4 | 2020 | 100 | 0.290 |
Why?
| | Clinical Trials as Topic | 4 | 2019 | 1044 | 0.280 |
Why?
| | Monocytes | 1 | 2011 | 563 | 0.280 |
Why?
| | Remission Induction | 4 | 2017 | 288 | 0.280 |
Why?
| | Child, Preschool | 15 | 2023 | 10997 | 0.280 |
Why?
| | Social Adjustment | 1 | 2008 | 62 | 0.280 |
Why?
| | Mutation | 2 | 2015 | 3946 | 0.270 |
Why?
| | Killer Cells, Natural | 3 | 2021 | 443 | 0.270 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 250 | 0.270 |
Why?
| | Carcinoma | 1 | 2009 | 238 | 0.260 |
Why?
| | Receptors, Antigen | 2 | 2017 | 16 | 0.260 |
Why?
| | Allografts | 3 | 2018 | 146 | 0.260 |
Why?
| | Gene Rearrangement | 2 | 2024 | 149 | 0.250 |
Why?
| | Lymphopoiesis | 2 | 2006 | 26 | 0.250 |
Why?
| | Neuroblastoma | 2 | 2021 | 160 | 0.250 |
Why?
| | Mice, Transgenic | 7 | 2021 | 2163 | 0.240 |
Why?
| | Interferon-gamma | 1 | 2009 | 789 | 0.240 |
Why?
| | Prognosis | 7 | 2020 | 4013 | 0.240 |
Why?
| | Unsupervised Machine Learning | 1 | 2025 | 22 | 0.240 |
Why?
| | Immunocompromised Host | 2 | 2010 | 202 | 0.230 |
Why?
| | Stem Cell Transplantation | 1 | 2006 | 176 | 0.230 |
Why?
| | Philadelphia Chromosome | 1 | 2024 | 18 | 0.230 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 1058 | 0.230 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2025 | 40 | 0.230 |
Why?
| | HIV Infections | 5 | 2008 | 2828 | 0.230 |
Why?
| | Tissue Donors | 4 | 2018 | 417 | 0.230 |
Why?
| | Disease Progression | 5 | 2021 | 2750 | 0.230 |
Why?
| | Unrelated Donors | 3 | 2023 | 39 | 0.230 |
Why?
| | Transplantation, Autologous | 5 | 2018 | 238 | 0.220 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2025 | 225 | 0.220 |
Why?
| | Treatment Outcome | 12 | 2025 | 10745 | 0.220 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2024 | 73 | 0.210 |
Why?
| | Lentivirus | 3 | 2019 | 56 | 0.210 |
Why?
| | T-Lymphocytes, Regulatory | 4 | 2017 | 387 | 0.210 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 2 | 2014 | 24 | 0.210 |
Why?
| | Combined Modality Therapy | 4 | 2021 | 1231 | 0.200 |
Why?
| | Interleukin-15 | 4 | 2014 | 97 | 0.200 |
Why?
| | Regeneration | 2 | 2004 | 195 | 0.200 |
Why?
| | Macrophages | 1 | 2011 | 1544 | 0.200 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2023 | 47 | 0.200 |
Why?
| | Genetic Vectors | 3 | 2019 | 317 | 0.190 |
Why?
| | Mice, SCID | 4 | 2019 | 366 | 0.190 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2021 | 188 | 0.190 |
Why?
| | Burkitt Lymphoma | 1 | 2022 | 60 | 0.190 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2002 | 86 | 0.190 |
Why?
| | Microglia | 1 | 2024 | 251 | 0.180 |
Why?
| | Gangliosides | 1 | 2021 | 20 | 0.180 |
Why?
| | Lymphopenia | 4 | 2011 | 62 | 0.180 |
Why?
| | Thrombocytopenia | 1 | 2023 | 198 | 0.180 |
Why?
| | Coculture Techniques | 2 | 2012 | 239 | 0.180 |
Why?
| | Bone Marrow | 3 | 2020 | 286 | 0.180 |
Why?
| | Capillary Leak Syndrome | 1 | 2020 | 12 | 0.170 |
Why?
| | Exotoxins | 1 | 2020 | 16 | 0.170 |
Why?
| | Recovery of Function | 1 | 2005 | 652 | 0.170 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2025 | 752 | 0.170 |
Why?
| | Macrophage Activation Syndrome | 1 | 2020 | 22 | 0.170 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2021 | 69 | 0.170 |
Why?
| | Anxiety | 1 | 2008 | 1031 | 0.170 |
Why?
| | Immunotoxins | 1 | 2020 | 55 | 0.170 |
Why?
| | Cyclophosphamide | 4 | 2023 | 247 | 0.170 |
Why?
| | Leukemia, B-Cell | 1 | 2020 | 13 | 0.170 |
Why?
| | Mice, Inbred NOD | 3 | 2019 | 600 | 0.160 |
Why?
| | Bacterial Toxins | 1 | 2020 | 105 | 0.160 |
Why?
| | B-Lymphocytes | 4 | 2018 | 846 | 0.160 |
Why?
| | Immunodominant Epitopes | 2 | 2012 | 28 | 0.160 |
Why?
| | Clinical Studies as Topic | 1 | 2019 | 10 | 0.160 |
Why?
| | Pediatrics | 1 | 2008 | 1094 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2019 | 12 | 0.160 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2021 | 135 | 0.160 |
Why?
| | Cell Proliferation | 6 | 2024 | 2475 | 0.160 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2019 | 17 | 0.160 |
Why?
| | Epitopes | 2 | 2018 | 480 | 0.150 |
Why?
| | Cell Membrane | 2 | 2020 | 735 | 0.150 |
Why?
| | Immunomodulation | 1 | 2019 | 98 | 0.150 |
Why?
| | In Vitro Techniques | 1 | 2020 | 1089 | 0.150 |
Why?
| | Multiple Myeloma | 1 | 2021 | 251 | 0.150 |
Why?
| | Immunologic Factors | 1 | 2020 | 236 | 0.150 |
Why?
| | History, 21st Century | 1 | 2019 | 212 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2012 | 1682 | 0.150 |
Why?
| | Cryopreservation | 1 | 2019 | 98 | 0.150 |
Why?
| | Down Syndrome | 1 | 2024 | 490 | 0.140 |
Why?
| | Cell- and Tissue-Based Therapy | 2 | 2018 | 80 | 0.140 |
Why?
| | Autoantigens | 2 | 2019 | 428 | 0.140 |
Why?
| | History, 20th Century | 1 | 2019 | 324 | 0.140 |
Why?
| | Follow-Up Studies | 5 | 2021 | 5106 | 0.140 |
Why?
| | Secondary Prevention | 1 | 2019 | 232 | 0.140 |
Why?
| | Membrane Proteins | 1 | 2004 | 1163 | 0.140 |
Why?
| | Fas Ligand Protein | 2 | 2019 | 59 | 0.140 |
Why?
| | Cell Division | 3 | 2012 | 796 | 0.140 |
Why?
| | Graft Survival | 3 | 2011 | 534 | 0.140 |
Why?
| | Inflammation Mediators | 1 | 2020 | 513 | 0.140 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 672 | 0.140 |
Why?
| | Protein Domains | 1 | 2019 | 289 | 0.140 |
Why?
| | Salvage Therapy | 2 | 2023 | 142 | 0.140 |
Why?
| | Chromatin | 2 | 2023 | 519 | 0.140 |
Why?
| | Cell Engineering | 1 | 2017 | 13 | 0.130 |
Why?
| | Immunophenotyping | 2 | 2020 | 319 | 0.130 |
Why?
| | Cell Culture Techniques | 1 | 2019 | 362 | 0.130 |
Why?
| | Lymph Nodes | 3 | 2013 | 492 | 0.130 |
Why?
| | Cytomegalovirus Infections | 1 | 2018 | 192 | 0.130 |
Why?
| | Spine | 1 | 2018 | 173 | 0.130 |
Why?
| | Retrospective Studies | 9 | 2023 | 15504 | 0.130 |
Why?
| | Stem Cell Research | 1 | 2016 | 1 | 0.130 |
Why?
| | CD4 Lymphocyte Count | 4 | 2008 | 269 | 0.130 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 122 | 0.130 |
Why?
| | Receptors, Calcium-Sensing | 1 | 2015 | 6 | 0.120 |
Why?
| | Infant | 8 | 2018 | 9395 | 0.120 |
Why?
| | Stem Cell Niche | 1 | 2016 | 54 | 0.120 |
Why?
| | Clone Cells | 1 | 2016 | 266 | 0.120 |
Why?
| | PAX5 Transcription Factor | 1 | 2015 | 14 | 0.120 |
Why?
| | Antineoplastic Agents | 3 | 2019 | 2122 | 0.120 |
Why?
| | STAT Transcription Factors | 1 | 2015 | 17 | 0.120 |
Why?
| | Janus Kinases | 1 | 2015 | 15 | 0.120 |
Why?
| | Gene Editing | 1 | 2016 | 79 | 0.120 |
Why?
| | Transcription Factors | 1 | 2023 | 1718 | 0.120 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 234 | 0.120 |
Why?
| | Aging | 3 | 2002 | 1864 | 0.120 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2015 | 26 | 0.120 |
Why?
| | Receptors, Cell Surface | 1 | 2017 | 382 | 0.120 |
Why?
| | Prospective Studies | 5 | 2023 | 7572 | 0.120 |
Why?
| | Myeloid Cells | 1 | 2016 | 148 | 0.120 |
Why?
| | Cell Line | 2 | 2017 | 2838 | 0.120 |
Why?
| | 4-1BB Ligand | 1 | 2014 | 7 | 0.120 |
Why?
| | Calgranulin B | 1 | 2014 | 10 | 0.110 |
Why?
| | Growth | 1 | 1994 | 60 | 0.110 |
Why?
| | Calgranulin A | 1 | 2014 | 11 | 0.110 |
Why?
| | Virus Replication | 1 | 2017 | 482 | 0.110 |
Why?
| | Models, Biological | 3 | 2009 | 1773 | 0.110 |
Why?
| | Survival Analysis | 2 | 2017 | 1321 | 0.110 |
Why?
| | Mice, 129 Strain | 1 | 2014 | 88 | 0.110 |
Why?
| | Erythrocytes | 1 | 2020 | 699 | 0.110 |
Why?
| | Growth Disorders | 1 | 1994 | 86 | 0.110 |
Why?
| | Genome | 1 | 2016 | 294 | 0.110 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1269 | 0.110 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2014 | 77 | 0.110 |
Why?
| | Attitude to Health | 2 | 2008 | 437 | 0.110 |
Why?
| | Phenotype | 4 | 2019 | 3189 | 0.110 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2014 | 87 | 0.110 |
Why?
| | Body Height | 1 | 1994 | 199 | 0.110 |
Why?
| | Alternative Splicing | 1 | 2015 | 229 | 0.100 |
Why?
| | Transduction, Genetic | 3 | 2019 | 126 | 0.100 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2014 | 173 | 0.100 |
Why?
| | Recombinant Proteins | 6 | 2011 | 1350 | 0.100 |
Why?
| | fas Receptor | 2 | 2019 | 95 | 0.100 |
Why?
| | Incidence | 2 | 2018 | 2792 | 0.100 |
Why?
| | Animals, Congenic | 1 | 2012 | 9 | 0.100 |
Why?
| | Radiation Chimera | 1 | 2012 | 30 | 0.100 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2012 | 60 | 0.100 |
Why?
| | Proteins | 1 | 2019 | 1008 | 0.100 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2012 | 51 | 0.100 |
Why?
| | CD3 Complex | 3 | 2017 | 106 | 0.100 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2012 | 48 | 0.100 |
Why?
| | Treatment Failure | 2 | 2014 | 354 | 0.100 |
Why?
| | Tumor Burden | 1 | 2013 | 309 | 0.100 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2012 | 71 | 0.100 |
Why?
| | Antigen-Presenting Cells | 2 | 2010 | 156 | 0.090 |
Why?
| | Chemokines | 1 | 2013 | 228 | 0.090 |
Why?
| | Tissue and Organ Procurement | 1 | 2016 | 314 | 0.090 |
Why?
| | Blood Component Removal | 1 | 2011 | 25 | 0.090 |
Why?
| | Body Weight | 2 | 2002 | 985 | 0.090 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 657 | 0.090 |
Why?
| | CD4-CD8 Ratio | 2 | 2019 | 22 | 0.090 |
Why?
| | Interleukin-6 | 1 | 2015 | 778 | 0.090 |
Why?
| | Methoxsalen | 1 | 2011 | 4 | 0.090 |
Why?
| | Brain Neoplasms | 2 | 2011 | 1235 | 0.090 |
Why?
| | Adenovirus Infections, Human | 1 | 2010 | 15 | 0.090 |
Why?
| | Spleen | 2 | 2011 | 514 | 0.090 |
Why?
| | Cytosine | 1 | 2010 | 49 | 0.090 |
Why?
| | Blood | 1 | 2011 | 107 | 0.080 |
Why?
| | Alleles | 1 | 2013 | 890 | 0.080 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2002 | 271 | 0.080 |
Why?
| | Organophosphonates | 1 | 2010 | 93 | 0.080 |
Why?
| | Hematopoiesis | 3 | 2016 | 190 | 0.080 |
Why?
| | Antiviral Agents | 2 | 2018 | 739 | 0.080 |
Why?
| | Acute Disease | 3 | 2023 | 1006 | 0.080 |
Why?
| | Ophthalmoplegia | 1 | 1989 | 8 | 0.080 |
Why?
| | Transplantation Immunology | 1 | 2009 | 34 | 0.080 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 1989 | 28 | 0.080 |
Why?
| | Laryngeal Neoplasms | 1 | 1989 | 39 | 0.080 |
Why?
| | Sarcoma | 1 | 2011 | 188 | 0.080 |
Why?
| | Intestinal Neoplasms | 1 | 2009 | 29 | 0.080 |
Why?
| | Hematopoietic System | 1 | 2008 | 8 | 0.080 |
Why?
| | Virus Diseases | 1 | 2011 | 213 | 0.070 |
Why?
| | Interleukin-12 | 1 | 2009 | 121 | 0.070 |
Why?
| | Cell Differentiation | 4 | 2023 | 1982 | 0.070 |
Why?
| | Sibling Relations | 1 | 2008 | 11 | 0.070 |
Why?
| | Substrate Specificity | 1 | 2009 | 371 | 0.070 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2008 | 47 | 0.070 |
Why?
| | Ultraviolet Rays | 1 | 2011 | 390 | 0.070 |
Why?
| | Lymphocyte Subsets | 2 | 2014 | 87 | 0.070 |
Why?
| | Psychology | 1 | 2008 | 85 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2014 | 4191 | 0.070 |
Why?
| | Lipopolysaccharides | 1 | 2011 | 886 | 0.070 |
Why?
| | Tumor Cells, Cultured | 1 | 2009 | 953 | 0.070 |
Why?
| | Biomarkers | 2 | 2016 | 4144 | 0.070 |
Why?
| | Macaca fascicularis | 2 | 2007 | 65 | 0.070 |
Why?
| | Skin Neoplasms | 1 | 2014 | 852 | 0.070 |
Why?
| | Immune Tolerance | 2 | 2010 | 362 | 0.060 |
Why?
| | Brain | 1 | 2018 | 2664 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 233 | 0.060 |
Why?
| | Ki-67 Antigen | 2 | 2004 | 111 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2022 | 1059 | 0.060 |
Why?
| | Middle Aged | 8 | 2025 | 33228 | 0.060 |
Why?
| | Immunologic Surveillance | 1 | 2004 | 25 | 0.060 |
Why?
| | Nitriles | 1 | 2024 | 172 | 0.050 |
Why?
| | Hemostasis | 1 | 2004 | 82 | 0.050 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1989 | 683 | 0.050 |
Why?
| | United States | 4 | 2018 | 14690 | 0.050 |
Why?
| | Obesity | 2 | 2022 | 2982 | 0.050 |
Why?
| | CD47 Antigen | 1 | 2023 | 38 | 0.050 |
Why?
| | Aged | 6 | 2025 | 23794 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2024 | 283 | 0.050 |
Why?
| | Autoimmune Diseases | 1 | 2006 | 460 | 0.050 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 2002 | 15 | 0.050 |
Why?
| | Histocompatibility Testing | 2 | 2014 | 126 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2022 | 182 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2022 | 346 | 0.050 |
Why?
| | Cohort Studies | 3 | 2014 | 5701 | 0.050 |
Why?
| | United Kingdom | 2 | 2009 | 310 | 0.050 |
Why?
| | Thymectomy | 1 | 2001 | 15 | 0.040 |
Why?
| | Pyrazoles | 1 | 2024 | 423 | 0.040 |
Why?
| | Pyrimidines | 1 | 2024 | 470 | 0.040 |
Why?
| | Protein Binding | 2 | 2019 | 2216 | 0.040 |
Why?
| | Body Mass Index | 1 | 2009 | 2375 | 0.040 |
Why?
| | HIV Protease Inhibitors | 1 | 2001 | 69 | 0.040 |
Why?
| | Ritonavir | 1 | 2001 | 74 | 0.040 |
Why?
| | Skin Transplantation | 1 | 2001 | 85 | 0.040 |
Why?
| | Cell Survival | 2 | 2019 | 1116 | 0.040 |
Why?
| | NF-kappa B | 1 | 2024 | 691 | 0.040 |
Why?
| | Lymphocytes | 1 | 2002 | 393 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2011 | 2639 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2020 | 303 | 0.040 |
Why?
| | Subcutaneous Emphysema | 1 | 1999 | 1 | 0.040 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2019 | 9 | 0.040 |
Why?
| | Single-Chain Antibodies | 1 | 2019 | 18 | 0.040 |
Why?
| | Vulva | 1 | 1999 | 24 | 0.040 |
Why?
| | K562 Cells | 1 | 2019 | 89 | 0.040 |
Why?
| | Mice, Nude | 1 | 2001 | 696 | 0.040 |
Why?
| | Up-Regulation | 3 | 2008 | 844 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 647 | 0.040 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 1999 | 21 | 0.040 |
Why?
| | Age Factors | 3 | 2011 | 3284 | 0.040 |
Why?
| | Transgenes | 1 | 2019 | 179 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 275 | 0.040 |
Why?
| | Immunization | 1 | 2001 | 411 | 0.040 |
Why?
| | Mental Status and Dementia Tests | 1 | 2018 | 26 | 0.040 |
Why?
| | Hallucinations | 1 | 2018 | 29 | 0.040 |
Why?
| | Confusion | 1 | 2018 | 28 | 0.040 |
Why?
| | Cancer Care Facilities | 1 | 2018 | 38 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 128 | 0.040 |
Why?
| | Risk Factors | 4 | 2018 | 10325 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 187 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 293 | 0.040 |
Why?
| | Steroids | 1 | 2018 | 167 | 0.030 |
Why?
| | Gene Order | 1 | 2017 | 26 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 191 | 0.030 |
Why?
| | Graft Rejection | 1 | 2001 | 620 | 0.030 |
Why?
| | Weight Loss | 1 | 2002 | 776 | 0.030 |
Why?
| | Advisory Committees | 1 | 2018 | 219 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 411 | 0.030 |
Why?
| | Transfection | 1 | 2019 | 941 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 685 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 729 | 0.030 |
Why?
| | Cell Cycle | 1 | 2019 | 601 | 0.030 |
Why?
| | Protein Engineering | 1 | 2017 | 97 | 0.030 |
Why?
| | Medical Oncology | 1 | 2018 | 288 | 0.030 |
Why?
| | Time Factors | 4 | 2008 | 6808 | 0.030 |
Why?
| | Ethics Committees, Research | 1 | 2016 | 41 | 0.030 |
Why?
| | Anti-HIV Agents | 1 | 2002 | 775 | 0.030 |
Why?
| | Research Subjects | 1 | 2016 | 41 | 0.030 |
Why?
| | Serine-Arginine Splicing Factors | 1 | 2015 | 22 | 0.030 |
Why?
| | Genetic Therapy | 1 | 2017 | 293 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2017 | 466 | 0.030 |
Why?
| | CD28 Antigens | 1 | 2015 | 53 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2008 | 5742 | 0.030 |
Why?
| | Health Policy | 1 | 2018 | 385 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2018 | 6032 | 0.030 |
Why?
| | Chimera | 1 | 2014 | 58 | 0.030 |
Why?
| | Transplantation Chimera | 1 | 2014 | 54 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2022 | 3265 | 0.030 |
Why?
| | Exons | 1 | 2015 | 351 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 816 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2001 | 2829 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 257 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2015 | 455 | 0.030 |
Why?
| | Reference Values | 1 | 1994 | 816 | 0.030 |
Why?
| | Transcriptome | 1 | 2019 | 969 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 809 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2016 | 399 | 0.020 |
Why?
| | Vidarabine | 1 | 2012 | 33 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 86 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 2014 | 254 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2015 | 423 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 813 | 0.020 |
Why?
| | Etoposide | 1 | 2012 | 158 | 0.020 |
Why?
| | Vincristine | 1 | 2012 | 116 | 0.020 |
Why?
| | Rituximab | 1 | 2012 | 176 | 0.020 |
Why?
| | Prednisone | 1 | 2012 | 239 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 951 | 0.020 |
Why?
| | Doxorubicin | 1 | 2012 | 362 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 49 | 0.020 |
Why?
| | Opportunistic Infections | 1 | 2009 | 45 | 0.020 |
Why?
| | Bone Neoplasms | 1 | 2012 | 247 | 0.020 |
Why?
| | Biomedical Research | 1 | 2016 | 688 | 0.020 |
Why?
| | Bacteremia | 1 | 2011 | 212 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1455 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 888 | 0.020 |
Why?
| | Risk | 1 | 2011 | 908 | 0.020 |
Why?
| | CD8 Antigens | 1 | 2008 | 75 | 0.020 |
Why?
| | Leukocytes | 1 | 2010 | 311 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 1989 | 351 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2015 | 2831 | 0.020 |
Why?
| | Cell Separation | 1 | 2008 | 317 | 0.020 |
Why?
| | HLA Antigens | 1 | 2008 | 237 | 0.020 |
Why?
| | HIV | 1 | 2008 | 234 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3555 | 0.020 |
Why?
| | Mass Screening | 1 | 1994 | 1267 | 0.020 |
Why?
| | Cell Polarity | 1 | 2007 | 141 | 0.020 |
Why?
| | Body Composition | 1 | 2009 | 679 | 0.020 |
Why?
| | Forkhead Transcription Factors | 1 | 2006 | 190 | 0.010 |
Why?
| | Catheter Ablation | 1 | 2009 | 349 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2006 | 316 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 2 | 1999 | 2667 | 0.010 |
Why?
| | Adiposity | 1 | 2009 | 518 | 0.010 |
Why?
| | Annexin A5 | 1 | 2004 | 25 | 0.010 |
Why?
| | Interleukins | 1 | 2006 | 250 | 0.010 |
Why?
| | Coloring Agents | 1 | 2004 | 87 | 0.010 |
Why?
| | Stromal Cells | 1 | 2004 | 112 | 0.010 |
Why?
| | Macaca mulatta | 1 | 2004 | 166 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2004 | 330 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1935 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 889 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 2022 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2009 | 825 | 0.010 |
Why?
| | bcl-2-Associated X Protein | 1 | 2002 | 56 | 0.010 |
Why?
| | Models, Genetic | 1 | 2004 | 599 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 2001 | 17 | 0.010 |
Why?
| | Temperature | 1 | 2004 | 675 | 0.010 |
Why?
| | Leukocyte Common Antigens | 1 | 2001 | 87 | 0.010 |
Why?
| | Kinetics | 1 | 2004 | 1664 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 337 | 0.010 |
Why?
| | Colon | 1 | 2002 | 282 | 0.010 |
Why?
| | Pubic Bone | 1 | 1999 | 6 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1242 | 0.010 |
Why?
| | Hyperbaric Oxygenation | 1 | 1999 | 39 | 0.010 |
Why?
| | Genotype | 1 | 2004 | 1914 | 0.010 |
Why?
| | Risk Assessment | 1 | 2008 | 3432 | 0.010 |
Why?
| | Radiography, Abdominal | 1 | 1999 | 45 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2009 | 2104 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2004 | 1430 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2007 | 5423 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1940 | 0.010 |
Why?
|
|
Fry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|